Purpose This study aimed to evaluate serum cytochrome c (cyto-c) levels as a novel role of tumor marker in patients with operable malignant tumors. Methods Serum cyto-c levels and lactate dehydrogenase (LD) activity were measured in a total of 257 cases (232 malignant and 25 benign). To identify the relationship between serum cyto-c and current tumor markers, six variables, such as gender, age, invasion, lymph node metastasis, distant metastasis, and LD, were analyzed by uni-and multivariate regression analysis methods. The test performance of serum cyto-c for the prediction of malignant behavior was evaluated by receiver operating characteristic (ROC) curves.
Introduction
Circulating tumor markers are used to deWne a particular disease entity in clinical settings for diagnosis, staging, and monitoring. Tumor markers are usually proteins released from dying tumor cells or elaborated by neoplastic cells. There are two subcategories of the proteins, speciWc and non-speciWc. Tumor speciWc proteins are expressed only in tumor cells, such as chimeric fusion proteins associated with malignant processes, leading to the development of a malignant clone. These protein markers are very useful for the detection and diagnosis of speciWc malignant tumors. On the other hand, non-speciWc proteins or markers related to malignant cells are onco-fetal or carcinogenic antigens, such as carcinoembryonic antigen (CEA), alphafetoprotein, prostate speciWc antigen (PSA), CA15.3, and CA19-9, all of which are still useful for screening, monitoring, staging, and prognosis, although their diagnostic speciWcity is not especially high. Recently, besides these classical tumor markers, cell speciWc proteins over-expressed in malignant cells have become available because diVerentiated wildtyped cells normally express these markers at a subtle and constant level but the corresponding tumor cells express it at a high level. For example, soluble IL-2 receptors, VEGF, and so on, are closely associated with the cell cycle, apoptosis, signal transduction, angiogenesis, and invasion (Holdenrieder and Stieber 2004) .
Cancer is characterized by cell division and cell death. However, there are no appropriate cell death markers available for use in a clinical setting, although the activity of serum LD is employed as a universal death marker. Recently, cytokeratine 18, nucleosomes, fragmented DNA, and cyto-c in serum have been discussed as novel markers for the evaluation of apoptotic death (Beachy and Repasky 2008) .
It has been reported that cytochrome c (cyto-c) is released into the culture medium after activation of the intrinsic apoptotic caspase pathway in vitro and some patients with hematological malignancies have high levels of serum cyto-c. Barczyk et al. (2005) also showed that the change in serum cyto-c levels is useful for monitoring of therapeutic responsiveness and prognostic prediction upto 3 years later. Therefore, this study addressed the potential use of serum cyto-c as a surrogate marker alternative to pathological assessment in patients with operable malignant tumors.
Patients and methods

Serum speciments
Serum specimens and clinical information were collected under the regulations of the Ethical Board criteria deWned by the Japanese Association of Laboratory Medicine. A total of 257 patients (232 malignant and 25 benign) was enrolled in this study. Serum cyto-c and LD were measured in all cases, and CEA and CA-19-9 were measured in 28 cases of gastric cancer and in 37 cases of colorectal cancer (CRC). All sera were stored at ¡40°C until measurement. Pretreatment serum cyto-c levels were measured using serum samples collected from individuals diagnosed as having lung, gastro-intestinal, colorectal, breast, uro-genital, ovaro-uterine cancers, and benign tumors. Benign tumors consisted of tubular adenoma of the colon, serous cystadenoma, thymoma, severe dysplasia of the uterus, moderate dysplasia of the urinary bladder, and prostatic hyperplasia. Almost all patients were operable status but nine were inoperable. No patient was treated preoperatively with either chemotherapy or radiation therapy. The median follow-up period was 6 months, ranging from 1 to 19 months. Of 249 cases available for histological examination, invasion and metastasis were evaluated according to the tumor-node-metastasis (TNM) staging system. The presence of distant metastasis was detected by image analysis.
Cytochrome c quantiWcation
Human cyto-c was quantiWed using an in-house electrochemiluminescence immunoassay method. Twenty L of serum sample diluted 1:11 with 200 L of reaction buVer was incubated with 3 £ 10 7 micro magnetic beads (Invitrogen, Carlsbad, USA) coated with anti-cyto-c monoclonal antibody for 9 min at 30°C. After the beads were washed two times with washing buVer, 200 L of another anti-cytoc monoclonal antibody coupled with ruthenium(II) Tris (bipyridyl)-N-hydroxysuccinimide ester [Ru(bpy)32 +] (BioVeris, Gaithersburg, USA) was added to the beads and incubated for 9 min at 30°C. After the beads were washed three times with washing buVer, the beads were conducted into the electrode and the photons (wavelength, 620 nm) emitted from the Ru(bpy) 32 + coupled to the anti-cyto-c monoclonal antibody were counted with a photo-multiplier tube. To quantify the cyto-c present in the serum sample, puriWed human cyto-c (R & D Systems, Minneapolis, USA) as a standard antigen was assayed in parallel. The above ECLIA procedures were carried out with an automatic ECLIA analyzer (Picolumi 8220; Sanko Junyaku, Tokyo, Japan). Then, serum LD was measured by the International Federation of Clinical Chemistry (IFCC)-recommended method. CEA and CA19-9 were measured based on chemiluminescence enzyme immunoassay technology using commercially available kits, LUMIPULUSEpicorna-CEA and PULUSE-picorna-CA-19-9 (SRL Inc, Tokyo, Japan).
Statistical analysis
DiVerences in the distribution of cyto-c with clinical and pathological feautures were used for univariate and multivariate analysis. Mann-Whitney U test and Kruskal-Wallis H test were used for univariate analysis. To compare the abilities of tumor markers to distinguish patients with r/o metastasis and invasion, receiver operating characteristic (ROC) curves were constructured. In addition, areas under the ROC curves (AUCs) with 95% conWdence intervals (CI) were calculated for cyto-c, LD, CEA, and CA19-9. The optimal cut-oV value for cyto-c was determined by Youden's index. Survival rates were calculated by the Kaplan-Meier method, and were compared with log-rank test. For all analyses, a two tailed P value of <0.05 was considered statistically signiWcant. Statistical analyses were performed using "StatFlex Ver.5.0" software.
Results
Distribution of serum cyto-c levels
The basic patient characteristics of enrolled patients are summarized in Table 1 . Of a total of 257 cases, the median cyto-c levels were 20.6 ng/mL (IQR;16.2-29.2, range 7.2-629.3) in 232 patients with malignant tumors and 15.5 ng/ mL (IQR; 11.8-19.4, range 8.5-52.5) in 25 patients with benign tumors, respectively (P = 0.002, Mann-Whitney U test). The median cyto-c level was 13.6 ng/mL (IQR; 11.7-19.9, range 6.2-46.2) in 36 samples with healthy volunteers.
Mean tumor size was 42.6 mm (range 5-110) in malignant tumor and 32.5 mm (range 5-140) in benign tumor. No correlation were seen between maximal tumor size and serum cyto-c levels of malignant tumors in 95 patients with malignant tumors (r = 0.258, Spearman's coeYcient).
Individual data were displayed as plots of the median and 5th, 25th, 75th, and 95th percentiles of the preoperative cyto-c levels in each group, as shown in Fig. 1 . No diVerence in each cyto-c level was observed among the 10 subtypes of malignant tumor (P = 0.362, Kruskal-Wallis H test), revealing that serum cyto-c was not speciWc for tumor types. Diagnostic sensitivity and speciWcity to discriminate malignant from benign tumors were 55.6 and 76.0% when the cut-oV was 19.4 ng/mL based on the maximization of Youden's index.
Twelve patients died during this study period, and six of them had cyto-c levels over 100 ng/mL, which indicates the potent prognostic value of cyto-c. Survival curves were compared among patient groups with diVerent serum cyto-c levels, <40, 40-99, and >100 ng/mL. The Kaplan-Meier curve revealed that survival was signiWcantly poorer in patients with the serum cyto-c level over 40 ng/mL (P < 0.0001, Hazard ratio 16.76, (95% conWdential interval 4.45-63.04) (Fig. 2) .
Performance of cyto-c in predicting the presence of invasion and metastasis
The results are shown in Table 2 . The cyto-c level was statistically associated with invasion (P < 0.0001), metastasis (P < 0.001), and high LD activity (P < 0.0001, MannWhitney U test). Multiple linear regression analysis also showed signiWcant association of the elevation of serum cyto-c levels with invasion (P = 0.0004), metastasis (P = 0.0262), and LD (P < 0.0001). The performance characteristics of serum cyto-c as a laboratory test were analyzed using the ROC curve for two predictive factors (metastasis and invasion) in comparison with LD, CEA, and CA19-9. The preoperative ROC-AUC of cyto-c was higher than those of the other markers, as shown in Fig. 3 [AUC for metastasis = 0.781 (95% CI = 0.711-0.852) and AUC for invasion = 0.802 (95%CI = 0.730-0.873)]. Based on the maximization of Youden's index, the optimal cut-oV values for cyto-c in preoperative patients with cancer were 22.7 ng/mL (sensitivity, 81.6%; speciWcity, 68.9%) for metastasis, and 22.3 ng/mL (sensitivity, 86.5%; speciWcity, 66.9%) for invasion. Validation of cyto-c for subtypes of tumor
To examine the usefulness of cyto-c in respective cancer types, the same analyses were conducted for 31 patients with gastric cancer and 44 patients with CRC. In gastric cancers, as shown in Table 3 , cyto-c at the preoperative stage was signiWcantly associated with advanced stage (P < 0.001), the presence of distance metastasis (P = 0.009), and progression (P = 0.031), CEA, CA19-9 and LD did not show statistically signiWcant associations. Moreover, the ROC-AUC for advanced stages was 0.913 for cyto-c, 0.677 for CEA, 0.792 for CA19-9, and 0.507 for LD. Next, for patients with CRC, as shown in Table 4 , the test performance characteristics of cyto-c as a tumor marker were equivalent to both CEA and LD, but higher than CA19-9.
Discussion
This study presents for the Wrst time the possibility of the use of serum cyto-c as a surrogate marker alternative to pathological assessment in patients with operable malignant tumors. The present study clariWed that cyto-c levels at the preoperative stage vary widely regardless of the diVerent subtypes of cancer and stratiWcation by serum cyto-c level can predict advanced status. Using uni-and multivariable analyses, this study also found that the elevation of serum cyto-c was closely associated with serum LD activity and the presence of invasion and metastasis equivalent to the advanced status classiWed according to the TNM classiWcation. Preoperative serum cyto-c levels were highly predictable for invasion and metastasis in patients diagnosed as having operable cancers. The test performance of cyto-c by ROC-AUC analysis was superior to those of the current tumor makers, LD, CEA, and CA19-9.
Increased serum cyto-c has already been reported by in vivo and in vitro studies in hematological malignancies (Barczyk et al. 2005 ) and benign disorders involving (40) b (32) c (43) d (25) e (10) f (23) g (27) h (17) i (15) j (25) Cyto-c > 100 ng/mL, n = 11 ** P < 0.0001, * P = 0.001 ** systemic cell death (Hosoya et al. 2005) . However, little is known about serum cyto-c associated with malignant solid tumors. The present Wndings are noteworthy to understand the origin of serum cyto-c in solid tumors and its usefulness as a tumor marker in patients with operable tumors. In addition, a strong association was evident between serum cyto-c and serum LD as well as the presence of invasion and distant metastasis. First of all, in terms of the origin of serum cyto-c, a previous study (Osaka et al. 2008) showed that hematological cell lines undergoing apoptosis by TRAIL Sensitivity can release cyto-c and LD into the culture medium, suggesting that both cyto-c and LD are mainly derived from dying tumor cells, and LD is employed as a universal death marker. Actually, on the origin of serum cyto-c, recent studies provide a signiWcant suggestion of a close relationship between apoptosis and tumorigenesis and especially con- cerning the grade of malignancy of individual tumors common to any subtype of cancer. For example, the growth of malignant tumors was shown to be under an imbalanced homeostasis of cell proliferation and cell death by apoptosis/necrosis (Harris 2002) . Manjo and Joris (1995) reported that cells in the center of solid tumors mainly die via necrosis and cells at the margins are preferentially eliminated by apoptosis. Such cell death was documented to be spontaneous apoptosis by TUNEL methods and to have a role in the development and progression of cancer. Such spontaneous apoptosis is also reported to be involved in mitochondrial cyto-c release and the activation of caspase-3 (Meggiato et al. 2000) . Thus, it was concluded that higher levels of apoptosis reXect higher grade of malignancy, which results in elevated serum cyto-c and becomes a negative prognostic index. Referring to these current concepts, the present results appear to be reasonable and valuable. Firstly, the elevation is demonstrable in only one-third of patients in any subtype of cancer, indicating that the elevation is not a common feature in cancers and results from individual cancer behavior, such as malignancy. On the other hand, serum cyto-c levels were independent of the size of the primary tumor and lymph node metastasis but dependent upon invasion and distant metastasis. This may represent only one facet of malignancy, such as a tumor type predisposed to metastasis being characterized by high apoptosis and high density of micro-vascularity (Tanaka et al. 2003) . Secondly, the elevation of 40 ng/ml or more at the preoperative time predicted poor prognosis, and the elevation of cyto-c levels was closely associated with invasion and metastasis. All of these Wndings support the close association of cyto-c with the biological property of high grade malignancy in tumors. The diagnostic sensitivity of cyto-c for the presence of cancers was low, 55.6%, so that it is unlikely to be recommended for screening of cancers. However, for preoperative patients who have a cancer, the ROC-AUCs of cyto-c for invasion and metastasis were superior, 0.802-0.781, compared to those of LD, CA19-9, and CEA. The diagnostic sensitivities of cyto-c for invasion and metastasis in patients with operable tumor were 81.6 and 86.5%, respectively. These values are probably tolerable for the clinical setting as a new tumor marker. To our knowledge, this is the Wrst report that cyto-c can predict malignant behavior.
This unique feature of cyto-c as a tumor marker was conWrmed in patients with gastric cancer and CRC. Of not, the cyto-c levels were associated with the advanced stage classiWed by the presence or absence of distant metastasis and progression according to the TNM classiWcation system. In particular, the ROC-AUC of cyto-c for metastasis in gastric cancer was high, 0.913. On the other hand, in patients with CRC, the test performance characteristics of cyto-c as a tumor marker were equivalent to both CEA and LD but higher than CA19-9.
The present study demonstrated that cyto-c is useful as a biomarker for pathological assessment involved in invasion and metastasis in patients with operable cancers. However, it must be repeated that cyto-c is useful as a tumor marker only in patients bearing cancer because serum cyto-c is also elevated in patients with non-malignant diseases, such as hepatitis, myocardial infarction (Alleyne et al. 2001) , systemic inXammatory response syndrome (Adachi et al. 2004) , and inXuenza-associated encephalopathy (Hosoya et al. 2006) . Accordingly, to further validate the usefulness of cyto-c as a a novel tumor biomarker, we need a largescale prospective study.
